Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 1;11(5):1221-1236.
doi: 10.1093/advances/nmaa058.

Potential Markers of Dietary Glycemic Exposures for Sustained Dietary Interventions in Populations without Diabetes

Edith Feskens  1 , Lorraine Brennan  2 , Pierre Dussort  3 , Matthieu Flourakis  3 , Lena M E Lindner  4   5 , David Mela  6 , Naila Rabbani  7   8 , Wolfgang Rathmann  4   5 , Frédérique Respondek  9 , Coen Stehouwer  10   11 , Stephan Theis  12 , Paul Thornalley  8   13 , Sophie Vinoy  14
Affiliations

Potential Markers of Dietary Glycemic Exposures for Sustained Dietary Interventions in Populations without Diabetes

Edith Feskens et al. Adv Nutr. .

Abstract

There is considerable interest in dietary and other approaches to maintaining blood glucose concentrations within the normal range and minimizing exposure to postprandial hyperglycemic excursions. The accepted marker to evaluate the sustained maintenance of normal blood glucose concentrations is glycated hemoglobin A1c (HbA1c). However, although this is used in clinical practice to monitor glycemic control in patients with diabetes, it has a number of drawbacks as a marker of efficacy of dietary interventions that might beneficially affect glycemic control in people without diabetes. Other markers that reflect shorter-term glycemic exposures have been studied and proposed, but consensus on the use and relevance of these markers is lacking. We have carried out a systematic search for studies that have tested the responsiveness of 6 possible alternatives to HbA1c as markers of sustained variation in glycemic exposures and thus their potential applicability for use in dietary intervention trials in subjects without diabetes: 1,5-anhydroglucitol (1,5-AG), dicarbonyl stress, fructosamine, glycated albumin (GA), advanced glycated end products (AGEs), and metabolomic profiles. The results suggest that GA may be the most promising for this purpose, but values may be confounded by effects of fat mass. 1,5-AG and fructosamine are probably not sensitive enough to the range of variation in glycemic exposures observed in healthy individuals. Use of measures based on dicarbonyls, AGEs, or metabolomic profiles would require further research into possible specific molecular species of interest. At present, none of the markers considered here is sufficiently validated and sensitive for routine use in substantiating the effects of sustained variation in dietary glycemic exposures in people without diabetes.

Keywords: 1,5-anhydroglucitol; HbA1c; advanced glycated end products; dicarbonyl stress; dietary intervention; fructosamine; glycated albumin; metabolomics; nondiabetic population; systematic review.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Blaak EE, Antoine JM, Benton D, Björck I, Bozzetto L, Brouns F, Diamant M, Dye L, Hulshof T, Holst JJ et al. .. Impact of postprandial glycaemia on health and prevention of disease. Obes Rev. 2012;13(10):923–84. - PMC - PubMed
    1. Faerch K, Alssema M, Mela DJ, Borg R, Vistisen D. Relative contributions of preprandial and postprandial glucose exposures, glycemic variability, and non-glycemic factors to HbA 1c in individuals with and without diabetes. Nutr Diabetes. 2018;8(1):38. - PMC - PubMed
    1. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L et al. .. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13. - PMC - PubMed
    1. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859–64. - PMC - PubMed
    1. Chan CL, Pyle L, Kelsey M, Newnes L, Zeitler PS, Nadeau KJ. Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia – 1,5-anhydroglucitol, fructosamine, and glycated albumin. Pediatr Diabetes. 2016;17(3):206–11. - PubMed

Publication types